查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1798083

化脓性汗腺炎市场预测（至 2032 年）：按临床分期、皮肤状况、治疗类型、给药途径、分销管道、最终用户和地区进行的全球分析

Hidradenitis Suppurativa Market Forecasts to 2032 - Global Analysis By Clinical Stage (Hurley Stage 1, Hurley Stage 2 and Hurley Stage 3), Skin Condition, Treatment Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球化脓性汗腺炎市场预计在 2025 年达到 8.5306 亿美元，到 2032 年将达到 13.4316 亿美元，预测期内的复合年增长率为 6.7%。

化脓性汗腺炎 (HS) 是一种慢性发炎性皮肤病，其特征是出现疼痛性结节、脓疡和窦道（窦道），通常发生在皮肤相互摩擦的部位，例如鼠蹊部、臀部和乳房下方。由于发炎和毛囊堵塞，该疾病经常復发，严重影响生活质量，并留下疤痕和不适。 HS 的确切病因尚不清楚，但可能的原因包括遗传、荷尔蒙变化、免疫系统异常、肥胖和吸烟。根据病情严重程度，可能需要长期治疗，包括改变生活方式、药物治疗和手术。此病在早期常被误诊。

根据印度的临床研究，全球盛行率为0.00033%至4.1%之间，且HS与高血压、肥胖、高血脂症、胰岛素抗性、METABOLIC INC.症候群、卵巢症候群（PCOS）等代谢紊乱有关。

提高疾病意识和盛行率

化脓性汗腺炎 (HS) 的发生率在全球范围内稳步上升，影响着数百万人，尤其是女性以及肥胖、METABOLIC INC.症候群或家族病史的人。历史上，HS 诊断不足，但由于近年来的宣传宣传活动、患者权益团体和教育倡议，该疾病已得到患者和医疗保健专业人员的广泛认可。这提高了诊断率，鼓励了早期就诊，并减少了病耻感。临床知识的累积也促进了严重程度分类的改进，这有助于选择最合适的治疗策略。随着越来越多的人获得早期诊断和治疗，对有效治疗的需求将不断增长，从而推动市场扩张。

生技药品治疗成本高昂

生技药品治疗的高昂成本是HS市场面临的最大障碍之一。虽然这些疗法比传统疗法更有效，但其高昂的成本往往限制了其广泛应用，尤其是在中低收入族群。Adalimumab、Secukinumab单抗和比美珠单抗等生技药品的年均费用高达数千美元，给患者和医疗保健系统都带来了巨大的压力。虽然新兴市场拥有保险覆盖和报销体系，但药物的可及性仍然不平等且有限。高昂的费用使许多患者无法开始治疗，甚至导致他们完全停止治疗。

标靶治疗和生技药品的成长

生技药品和标靶治疗的持续进展代表着HS最大的市场机会之一。儘管Humira、Cosentyx和Vimzerex等现有生技药品已经彻底改变了治疗方式，但下一代生技药品、JAK抑制剂和口服小分子化合物正处于研发阶段，这些化合物具有更高的疗效和更便捷的潜力。这些创新药物旨在解决尚未满足的需求，例如抗治疗性、注射疲劳和疗效反应率的差异性。日益激烈的竞争以及现有生技药品在HS治疗中的应用扩展，也可能降低成本并改善药物的可及性。如果企业成功推出更安全、更有效、更独特的治疗方法，就能占据相当大的市场。

专利到期，竞争激烈

HS 治疗市场竞争日益激烈，市场上已有许多标靶治疗和生技药品，还有更多正在研发中。这种竞争虽然增加了治疗选择，但也危及现有疗法的市场占有率和定价权。当关键生技药品（例如 Humira）的专利到期时，它们为开发生物相似药开闢了可能性，这可能会降低老字型大小企业的利润。激烈的竞争也可能导致激进的定价策略，从而降低行业利润率。此外，如果公司无法透过更好的给药系统、更高的安全性或独特的作用机制来实现产品的差异化，那么在这个快速变化的治疗市场中，就有可能落后。

COVID-19的影响

新冠疫情对化脓性汗腺炎 (HS) 市场产生了多重影响。大范围的封锁和医疗体系的中断最初导致诊断延迟、皮肤科医生就诊次数减少以及正在进行的治疗中断，尤其是对于需要去医院或诊所就诊生技药品的患者而言。许多临床试验的暂停也减缓了新治疗方法的开发。同时，疫情加速了数位健康平台和远端医疗的普及，增强了后续护理和远距患者管理。此外，人们对慢性病管理的认识不断提高以及对强大医疗保健系统的需求，导致近期 HS 研发资金激增。

预计肿胀样病变部分将是预测期内最大的

预计在预测期内，疖状病变领域将占据最大的市场占有率。这些病灶通常表现为疼痛肿胀的肿块，类似臀部、鼠蹊部或腋窝反覆出现的疖子。这些病变经常破裂、流脓并引起剧烈疼痛，导致许多患者就医。疖状病变是诊断、治疗和研究的主要焦点，因此，它们在 HS 各个阶段的高发病率占据了市场主导地位。因此，治疗这些病变是大多数治疗方法和临床研究的首要重点。

预计皮肤科诊所部门在预测期内的复合年增长率最高

预计皮肤科专科诊所细分市场将在预测期内达到最高成长率。对先进专业治疗的需求日益增长是这一增长的主要驱动力，因为HS通常需要标靶治疗、生技药品和外科手术，而这些治疗最好由皮肤科医生处理。患者更青睐这些诊所，因为他们能够全面处理复杂病例，并获得尖端治疗方案，并能准确诊断。此外，疾病认知度的提高、持续的临床试验以及精通慢性皮肤病的皮肤科医生的存在，也促进了该市场的发展。随着医疗保健系统越来越重视专科门诊护理，HS治疗的应用也越来越集中在皮肤科诊所。

占比最高的地区

预计北美地区将在预测期内占据最大的市场占有率，这得益于 HS 的高盛行率、患者和医疗保健专业人员对 HS 的高度认识，以及生技药品等尖端治疗方案的广泛可用性。该地区完善的医疗保健基础设施、优惠的报销政策以及创新治疗方法的早期核准，为患者提供广泛的治疗机会。领先製药公司的存在和正在进行的临床试验进一步加强了治疗创新和应用。此外，广泛的患者权益倡导和支持系统有助于长期疾病管理和早期诊断，巩固了北美在全球 HS 市场的主导地位。

复合年增长率最高的地区

预计亚太地区将在预测期内呈现最高的复合年增长率，这得益于尖端皮肤病护理服务日益普及、医疗保健支出不断增长以及人们对该疾病的认识不断提高。由于肥胖、荷尔蒙失调和文明病的普遍存在，中国、印度和日本等国家的 HS 发病率也在上升。政府和私人公司正在建设医疗保健基础设施，而製药公司则透过合作伙伴关係、分级定价和患者支援计划扩大其业务范围。此外，数位健康平台和远端医疗的快速普及也扩大了专家咨询的管道。这些因素共同使亚太地区成为 HS 治疗成长率最高的地区。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场参与企业进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 透过产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 二手研究资料
    • 先决条件

第三章市场走势分析

  • 介绍
  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球化脓性汗腺炎市场（依临床阶段）

  • 介绍
  • 哈雷第一阶段
  • 哈雷2级
  • 哈雷3级

6. 全球化脓性汗腺炎市场（依皮肤状况）

  • 介绍
  • 毛囊炎
  • 肿胀样病变
  • 深部结节
  • 痤疮样病变
  • 其他的

7. 全球化脓性汗腺炎市场（依治疗类型）

  • 介绍
  • 药理
    • 抗生素
    • 生技药品
    • 荷尔蒙疗法
    • 皮质类固醇
  • 治疗
    • 手术切除
    • 雷射治疗
    • 动态疗法（PDT）
    • 切开引流
  • 其他治疗类型

8. 全球化脓性汗腺炎市场（依给药途径）

  • 介绍
  • 口服
  • 肠外（注射）
  • 局部的
  • 其他的

9. 全球化脓性汗腺炎市场（依通路）

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局
  • 专业经销商
  • 其他的

第 10 章全球化脓性汗腺炎市场（依最终用户）

  • 介绍
  • 医院
  • 专科皮肤科诊所
  • 居家照护
  • 其他的

第 11 章全球化脓性汗腺炎市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Amgen Inc
  • Johnson & Johnson Private Limited
  • MoonLake Immunotherapeutics Inc
  • Boehringer Ingelheim Inc
  • Sanofi
  • UCB Biopharma
  • Kymera Therapeutics
  • Priovant Therapeutics
  • UNION Therapeutics
  • Incyte Corporation
  • CSL Behring
Product Code: SMRC30453

According to Stratistics MRC, the Global Hidradenitis Suppurativa Market is accounted for $853.06 million in 2025 and is expected to reach $1343.16 million by 2032 growing at a CAGR of 6.7% during the forecast period. Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition characterized by the development of painful nodules, abscesses, and tunnels (sinus tracts) typically occurring in areas where skin rubs together, such as the armpits, groin, buttocks, and under the breasts. Hair follicle inflammation and blockage cause the disease to flare up frequently, which can have a major negative influence on quality of life and leave scars and discomfort behind. Although the precise cause of HS is unknown, potential causes include genetics, hormonal changes, immune system dysregulation, obesity, and smoking. Depending on its severity, it may necessitate long-term management that includes lifestyle changes, medication, or surgery. It is frequently misdiagnosed in its early stages.

According to Indian clinical research, worldwide prevalence ranges from 0.00033% to 4.1%, and HS is associated with metabolic derangements-like hypertension, obesity, hyperlipidemia, insulin resistance, metabolic syndrome, and polycystic ovarian syndrome (PCOS).

Market Dynamics:

Driver:

Growing illness awareness and prevalence

The prevalence of Hidradenitis Suppurativa (HS) is steadily increasing worldwide, affecting millions, particularly women and individuals with obesity, metabolic syndrome, or a family history of the condition. Although historically under diagnosed, the disease is now more widely recognized by patients and medical professionals owing to recent awareness campaigns, patient advocacy groups, and educational initiatives. This has improved diagnostic rates, promoted earlier consultations, and lessened stigma. Improved disease severity classification brought about by growing clinical knowledge also helps choose the best course of treatment. As more people receive early diagnosis and treatment, there will likely be a greater need for efficient treatments, which will drive market expansion.

Restraint:

Expensive cost of biologic treatments

The high expense of biologic therapies is one of the biggest barriers to the HS market. Although these treatments are more effective than traditional methods, their cost frequently prevents them from being widely available, particularly in areas with low and middle incomes. Adalimumab, secukinumab, and bimekizumab are examples of biologics that can cost thousands of dollars per patient each year, putting a strain on both individuals and healthcare systems. Even though developed markets have insurance coverage and reimbursement programs, access is still unequal and limited. The exorbitant expenses prevent many patients from starting treatment or from stopping it altogether, which prevent the best possible adoption and general market growth.

Opportunity:

Growth of targeted and biologic treatments

The ongoing advancement of biologics and targeted therapies represents one of the largest market opportunities in HS. Treatment has already been revolutionized by current biologics like Humira, Cosentyx, and Bimzelx; however, next-generation biologics, JAK inhibitors, and oral small molecules with potentially higher efficacy and convenience are also in the therapeutic pipeline. Unmet needs like treatment resistance, injection fatigue, and variable response rates are what these innovative agents seek to address. Increased competition and the expansion of indications for currently available biologics into HS may also lower costs and improve access. Businesses have the potential to gain a sizable portion of the market if they can successfully launch safer, more effective, and unique treatments.

Threat:

Patent expiration and fierce competition

The market for HS therapeutics is getting more and more competitive, with numerous targeted therapies and biologics already on the market and numerous others in development. This competition increases treatment options, but it also puts current medications' market share and pricing power at risk. Leading biologics' patent expirations, like those of Humira, allow for the development of biosimilars, which may lower profits for well-established companies. Intense rivalry may also lead to aggressive pricing tactics, which would reduce industry profit margins. Moreover, businesses that don't differentiate their products with better delivery systems, enhanced safety, or distinctive mechanisms of action run the risk of falling behind in this rapidly changing therapeutic market.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the Hidradenitis Suppurativa (HS) market. Widespread lockdowns and disruptions to the healthcare system initially caused delays in diagnosis, fewer consultations with dermatologists, and disruptions in ongoing treatment, especially for patients who needed to visit a hospital or clinic for biologics. The development of new treatments was also slowed by the suspension of numerous clinical trials. On the other hand, the pandemic hastened the adoption of digital health platforms and telemedicine, which enhanced follow-up care and remote patient management. Additionally, there has been a recent surge in funding for HS research and treatment development due to increased awareness of managing chronic diseases and the need for robust healthcare systems.

The boil-like lesions segment is expected to be the largest during the forecast period

The boil-like lesions segment is expected to account for the largest market share during the forecast period. The most prevalent and clinically significant form of the disease are these lesions, which frequently manifest as painful, swollen lumps that resemble recurring boils in places like the buttocks, groin, and armpits. They frequently burst, release pus, and cause excruciating pain, which prompts many patients to seek medical help. Since boil-like lesions are the main focus of diagnosis, treatment, and research, their high prevalence throughout all stages of HS accounts for their market dominance. As a result, managing this segment is a major focus of the majority of therapeutic approaches and clinical trials.

The specialty dermatology clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the specialty dermatology clinics segment is predicted to witness the highest growth rate. The rising need for sophisticated and specialized care is the main driver of this growth, since HS frequently necessitates targeted treatments, biologics, and surgical procedures that are best handled by dermatology specialists. These clinics are preferred by patients due to their thorough handling of complex cases, access to cutting-edge treatments, and accurate diagnosis. Additionally, this market is strengthened by growing awareness of the illness, ongoing clinical trials, and the availability of dermatologists with expertise in chronic skin conditions. The adoption of HS treatments is increasingly concentrated in dermatology clinics as healthcare systems place an emphasis on specialized outpatient care.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the disease's high prevalence, patients' and healthcare professionals' strong awareness of it, and the broad availability of cutting-edge treatment options like biologics. Broad patient access is supported by the region's well-established healthcare infrastructure, advantageous reimbursement practices, and early regulatory approvals of innovative therapies. Treatment innovation and adoption are further bolstered by the presence of top pharmaceutical companies and ongoing clinical trials. Furthermore, expanding patient advocacy initiatives and support systems has helped with long-term disease management and early diagnosis, solidifying North America's leading position in the global HS market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, increased access to cutting-edge dermatology care, increased healthcare spending, and growing disease awareness. In nations like China, India, and Japan, the incidence of HS is also rising due to the prevalence of obesity, hormonal imbalances, and lifestyle-related illnesses. Infrastructure is being upgraded by governments and private healthcare providers, and pharmaceutical companies are growing their footprints through collaborations, tiered pricing, and patient support initiatives. Additionally, the quick uptake of digital health platforms and telemedicine is opening up access to expert consultations. Together, these elements make Asia-Pacific the region with the fastest rate of growth for HS treatments.

Key players in the market

Some of the key players in Hidradenitis Suppurativa Market include AbbVie Inc., Novartis AG, Eli Lilly and Company, Pfizer Inc., Amgen Inc, Johnson & Johnson Private Limited, MoonLake Immunotherapeutics Inc, Boehringer Ingelheim Inc, Sanofi, UCB Biopharma, Kymera Therapeutics, Priovant Therapeutics, UNION Therapeutics, Incyte Corporation and CSL Behring.

Key Developments:

In May 2025, Eli Lilly and Company and Purdue University announced a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years. This partnership, which has the potential to be the largest ever industry-academic agreement of its kind in the United States, will seek to accelerate innovation at every stage of the pharmaceutical pipeline.

In February 2025, AbbVie and Xilio Therapeutics, Inc. announced collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology. Xilio has developed a proprietary, clinically-validated platform technology for tumor-activated biologics.

In February 2025, Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront payment of $925m. The transaction includes $2.15bn of potential additional payments, contingent on regulatory and sales milestones.

Clinical Stages Covered:

  • Hurley Stage 1
  • Hurley Stage 2
  • Hurley Stage 3

Skin Conditions Covered:

  • Folliculitis
  • Boil-like Lesions
  • Deep Nodules
  • Acneiform Lesions
  • Other Skin Conditions

Treatment Types Covered:

  • Pharmacological
  • Procedural
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Parenteral (Injectables)
  • Topical
  • Other Route of Administration

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Distributors
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Specialty Dermatology Clinics
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hidradenitis Suppurativa Market, By Clinical Stage

  • 5.1 Introduction
  • 5.2 Hurley Stage 1
  • 5.3 Hurley Stage 2
  • 5.4 Hurley Stage 3

6 Global Hidradenitis Suppurativa Market, By Skin Condition

  • 6.1 Introduction
  • 6.2 Folliculitis
  • 6.3 Boil-like Lesions
  • 6.4 Deep Nodules
  • 6.5 Acneiform Lesions
  • 6.6 Other Skin Conditions

7 Global Hidradenitis Suppurativa Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Pharmacological
    • 7.2.1 Antibiotics
    • 7.2.2 Biologics
    • 7.2.3 Hormonal Therapy
    • 7.2.4 Corticosteroids
  • 7.3 Procedural
    • 7.3.1 Surgical Excision
    • 7.3.2 Laser Therapy
    • 7.3.3 Photodynamic Therapy (PDT)
    • 7.3.4 Incision and Drainage
  • 7.4 Other Treatment Types

8 Global Hidradenitis Suppurativa Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parenteral (Injectables)
  • 8.4 Topical
  • 8.5 Other Route of Administration

9 Global Hidradenitis Suppurativa Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Specialty Distributors
  • 9.6 Other Distribution Channels

10 Global Hidradenitis Suppurativa Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Dermatology Clinics
  • 10.4 Homecare Settings
  • 10.5 Other End Users

11 Global Hidradenitis Suppurativa Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AbbVie Inc.
  • 13.2 Novartis AG
  • 13.3 Eli Lilly and Company
  • 13.4 Pfizer Inc.
  • 13.5 Amgen Inc
  • 13.6 Johnson & Johnson Private Limited
  • 13.7 MoonLake Immunotherapeutics Inc
  • 13.8 Boehringer Ingelheim Inc
  • 13.9 Sanofi
  • 13.10 UCB Biopharma
  • 13.11 Kymera Therapeutics
  • 13.12 Priovant Therapeutics
  • 13.13 UNION Therapeutics
  • 13.14 Incyte Corporation
  • 13.15 CSL Behring

List of Tables

  • Table 1 Global Hidradenitis Suppurativa Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Hidradenitis Suppurativa Market Outlook, By Clinical Stage (2024-2032) ($MN)
  • Table 3 Global Hidradenitis Suppurativa Market Outlook, By Hurley Stage 1 (2024-2032) ($MN)
  • Table 4 Global Hidradenitis Suppurativa Market Outlook, By Hurley Stage 2 (2024-2032) ($MN)
  • Table 5 Global Hidradenitis Suppurativa Market Outlook, By Hurley Stage 3 (2024-2032) ($MN)
  • Table 6 Global Hidradenitis Suppurativa Market Outlook, By Skin Condition (2024-2032) ($MN)
  • Table 7 Global Hidradenitis Suppurativa Market Outlook, By Folliculitis (2024-2032) ($MN)
  • Table 8 Global Hidradenitis Suppurativa Market Outlook, By Boil-like Lesions (2024-2032) ($MN)
  • Table 9 Global Hidradenitis Suppurativa Market Outlook, By Deep Nodules (2024-2032) ($MN)
  • Table 10 Global Hidradenitis Suppurativa Market Outlook, By Acneiform Lesions (2024-2032) ($MN)
  • Table 11 Global Hidradenitis Suppurativa Market Outlook, By Other Skin Conditions (2024-2032) ($MN)
  • Table 12 Global Hidradenitis Suppurativa Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 13 Global Hidradenitis Suppurativa Market Outlook, By Pharmacological (2024-2032) ($MN)
  • Table 14 Global Hidradenitis Suppurativa Market Outlook, By Antibiotics (2024-2032) ($MN)
  • Table 15 Global Hidradenitis Suppurativa Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 16 Global Hidradenitis Suppurativa Market Outlook, By Hormonal Therapy (2024-2032) ($MN)
  • Table 17 Global Hidradenitis Suppurativa Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 18 Global Hidradenitis Suppurativa Market Outlook, By Procedural (2024-2032) ($MN)
  • Table 19 Global Hidradenitis Suppurativa Market Outlook, By Surgical Excision (2024-2032) ($MN)
  • Table 20 Global Hidradenitis Suppurativa Market Outlook, By Laser Therapy (2024-2032) ($MN)
  • Table 21 Global Hidradenitis Suppurativa Market Outlook, By Photodynamic Therapy (PDT) (2024-2032) ($MN)
  • Table 22 Global Hidradenitis Suppurativa Market Outlook, By Incision and Drainage (2024-2032) ($MN)
  • Table 23 Global Hidradenitis Suppurativa Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 24 Global Hidradenitis Suppurativa Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 25 Global Hidradenitis Suppurativa Market Outlook, By Oral (2024-2032) ($MN)
  • Table 26 Global Hidradenitis Suppurativa Market Outlook, By Parenteral (Injectables) (2024-2032) ($MN)
  • Table 27 Global Hidradenitis Suppurativa Market Outlook, By Topical (2024-2032) ($MN)
  • Table 28 Global Hidradenitis Suppurativa Market Outlook, By Other Route of Administration (2024-2032) ($MN)
  • Table 29 Global Hidradenitis Suppurativa Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 30 Global Hidradenitis Suppurativa Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 31 Global Hidradenitis Suppurativa Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 32 Global Hidradenitis Suppurativa Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 33 Global Hidradenitis Suppurativa Market Outlook, By Specialty Distributors (2024-2032) ($MN)
  • Table 34 Global Hidradenitis Suppurativa Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
  • Table 35 Global Hidradenitis Suppurativa Market Outlook, By End User (2024-2032) ($MN)
  • Table 36 Global Hidradenitis Suppurativa Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 37 Global Hidradenitis Suppurativa Market Outlook, By Specialty Dermatology Clinics (2024-2032) ($MN)
  • Table 38 Global Hidradenitis Suppurativa Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 39 Global Hidradenitis Suppurativa Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.